Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chronocort vs Immediate-Release Hydrocortisone in Congenital Adrenal Hyperplasia
NCT05063994Phase 3Completed
- Sponsor
- Neurocrine Biosciences
- Start
- May 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of hydrocortisone modified-release in congenital adrenal hyperplasia (CAH), sponsored by Neurocrine Biosciences. Started May 2022; status: completed.
02
Drugs
hydrocortisone modified-release
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on NCT05063994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05063994.